New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - hydrochlorothiazide 12.5mg; losartan potassium 50mg;   - film coated tablet - 50mg/12.5mg - active: hydrochlorothiazide 12.5mg losartan potassium 50mg   excipient: colloidal silicon dioxide hypromellose lactose monohydrate macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water   quinoline yellow starch titanium dioxide - for the treatment of hypertension, for patients in whom combination therapy is appropriate

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - hydrochlorothiazide 12.5mg; losartan potassium 50mg - film coated tablet - 50mg/12.5mg - active: hydrochlorothiazide 12.5mg losartan potassium 50mg excipient: hypromellose lactose monohydrate macrogol 4000 magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc quinoline yellow titanium dioxide - losartan hctad is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - losartan potassium; hydrochlorothiazide - oral tablet - 50mg ; 12.5mg

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hydrochlorothiazide 12.5mg;  ;  ; losartan potassium 50mg;   - film coated tablet - 50mg/12.5mg - active: hydrochlorothiazide 12.5mg     losartan potassium 50mg   excipient: carnauba wax hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose quinoline yellow starch titanium dioxide - hypertension hyzaar is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy hyzaar is a combination of losartan (cozaar) and hydrochlorothiazide. in patients with hypertension and left ventricular hypertrophy, losartan, often in combination with hydrochlorothiazide, reduces the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.

United States - English - NLM (National Library of Medicine)

avpak - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - hydrochlorothiazide 12.5 mg - losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, f

Canada - English - Health Canada

jubilant generics limited - hydrochlorothiazide; losartan potassium - tablet - 12.5mg; 50mg - hydrochlorothiazide 12.5mg; losartan potassium 50mg - angiotensin ii receptor antagonists

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - hydrochlorothiazide 12.5 mg - losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, f

Canada - English - Health Canada

mylan pharmaceuticals ulc - losartan potassium; hydrochlorothiazide - tablet - 50mg; 12.5mg - losartan potassium 50mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

mint pharmaceuticals inc - losartan potassium; hydrochlorothiazide - tablet - 50mg; 12.5mg - losartan potassium 50mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

pharmascience inc - losartan potassium; hydrochlorothiazide - tablet - 50mg; 12.5mg - losartan potassium 50mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists